BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Philogen signs drug discovery contract with J & J

24 January 2019 | News

The collaboration was facilitated by Johnson & Johnson Innovation LLC

Philogen S.p.A., a privately-owned biotechnology company, has announced through its wholly-owned Swiss subsidiary, Philochem AG, a collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, to discover new small molecule-based therapeutics utilizing Philochem's novel lead-generation technologies. The collaboration was facilitated by Johnson & Johnson Innovation LLC.

"We are extremely pleased to establish a new collaboration with Janssen, one of the leaders in the discovery and development of novel pharmaceuticals, with an impressive track record in developing small-molecule based therapeutics. We hope our technology will contribute to bringing innovative treatment for serious unmet medical needs," commented Prof. Dario Neri, co-founder and President of the Scientific Advisory Board of Philogen.

No financial details of the agreement were released.